

chain nodes :

1 2 3 4 5 6 7 8 9 10 11 13 14 18 19 20 22 23 24

ring/chain nodes :

21

chain bonds :

1-11 1-2 1-22 2-3 2-9 3-4 3-7 4-5 5-6 6-8 6-13 9-10 13-14
18-21 18-19 18-20 23-24

exact/norm bonds :

1-2 1-22 3-7 5-6 6-8 13-14 18-21 18-19 18-20 23-24

exact bonds :

1-11 2-3 2-9 3-4 4-5 6-13 9-10

G1:C,O,S,Cb,Cy,Hy,N

G2:C,O

G3:[*1],[*2]

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS
9:CLASS 10:CLASS 11:CLASS 13:CLASS 14:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS


09/284,424

L4 ANSWER 1 OF 36 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1999:152298 CAPLUS
DOCUMENT NUMBER: 130:182770
TITLE: Preparation of (N-substituted)-2-indolyl dipeptides
as inhibitors of the ICE/ced-3 family of cysteine
proteases
INVENTOR(S): Karanewsky, Donald S.; Bai, Xu
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 767,175.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5877197	A	19990302	US 1997-928989	19970912
US 5869519	A	19990209	US 1996-767175	19961216

PRIORITY APPLN. INFO.: US 1996-767175 19961216
OTHER SOURCE(S): MARPAT 130:182770
IT **204919-40-4P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (N-substituted)indolyl dipeptides as inhibitors of the interleukin-1.beta. converting enzyme and related proteases)
RN 204919-40-4 CAPLUS
CN Benzoic acid, 2,6-dichloro-,
4-carboxy-3-[[[(2S)-2-[[[(1,3-dimethyl-1H-indol-2-yl)carbonyl]amino]-3-methyl-1-oxobutyl]amino]-2-oxobutyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 36 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1999:136764 CAPLUS
DOCUMENT NUMBER: 130:196957
TITLE: Preparation of bicyclic peptide derivatives as
interleukin-1.beta. converting enzyme inhibitors
INVENTOR(S): Batchelor, Mark James; Bebbington, David; Bemis, Guy
W.; Fridman, Wolf Herman; Gillespie, Roger John;
Golec, Julian M. C.; Lauffer, David J.; Livingston,


09/284,424

D.: David J.; Matharu, Saroop Singh; Mullican, Michael
PATENT ASSIGNEE(S): Murcko, Mark A.; Murdoch, Robert; Zelle, Robert E.
SOURCE: Vertex Pharmaceuticals Incorporated, USA
575,641. U.S., 189 pp., Cont.-in-part of U.S. Ser. No.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5874424	A	19990223	US 1996-598332	19960208
WO 9722619	A2	19970626	WO 1996-US20843	19961220
WO 9722619	A3	19971016		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9715222	A1	19970714	AU 1997-15222	19961220
EP 869967	A2	19981014	EP 1996-945318	19961220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 9802597	A	19980812	NO 1998-2597	19980605
PRIORITY APPLN. INFO.:				
			US 1995-575641	19951220
			US 1996-598332	19960208
			US 1996-712878	19960912
			US 1996-31495	19961126
			US 1996-761483	19961206
			WO 1996-US20843	19961220
OTHER SOURCE(S): MARPAT 130:196957				
IT 175209-21-9P 175209-22-0P 175209-83-3P 192757-64-5P				
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(prepn. of bicyclic peptide derivs. as interleukin-1.beta. converting enzyme inhibitors)				
RN 175209-21-9 CAPLUS				
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[2-oxo-3-[[[(phenylmethoxy)carbonyl]amino]-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry. Rotation (-).


09/284,424



RN 175209-22-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(phenylmethyl)-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 175209-83-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[(3S)-2,3,4,5-tetrahydro-2-oxo-5-(1-oxo-3-phenylpropyl)-3-[(1-oxo-3-phenylpropyl)amino]-1H-1,5-benzodiazepin-1-yl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/284,424



RN 192757-64-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(3S)-3-(benzoylamino)-2,3,4,5-tetrahydro-5-(methylsulfonyl)-2-oxo-1H-1,5-benzodiazepin-1-yl]acetyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1999:59441 CAPLUS

DOCUMENT NUMBER: 130:261459

TITLE: Three-Dimensional Quantitative Structure-Activity Relationship of Interleukin 1-.beta. Converting

Enzyme

Inhibitors: A Comparative Molecular Field Analysis Study

AUTHOR(S): Kulkarni, Santosh S.; Kulkarni, Vithal M.

CORPORATE SOURCE: Department of Chemical Technology Pharmaceutical

09/284,424

India
SOURCE: Division, University of Mumbai, Mumbai, 400 019,

J. Med. Chem. (1999), 42(3), 373-380

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 151272-16-1 151272-17-2 153088-74-5

154674-81-4 154674-82-5 154674-84-7

154674-86-9 173305-25-4 173305-41-4

205324-41-0 222406-86-2 222406-88-4

222406-90-8 222406-92-0 222406-93-1


222406-94-2 222406-96-4

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (QSAR of interleukin 1.beta. converting enzyme inhibitors: comparative mol. field anal. study)

RN 151272-16-1 CAPLUS

CN L-Alaninamide, N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-3-[[2,6-bis(trifluoromethyl)benzoyl]oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 151272-17-2 CAPLUS

CN L-Alaninamide, N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-3-(benzoyloxy)-1-(carboxymethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153088-74-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[(2S)-3-methyl-1-oxo-2-

09/284,424

[[(phenylmethoxy) carbonyl] amino] butyl] amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 154674-81-4 CAPLUS

CN L-Alaninamide, N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-1-(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


—OH

RN 154674-82-5 CAPLUS

CN L-Alaninamide, N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-3-[[2,6-bis(trifluoromethyl)benzoyl]oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—OH

RN 154674-84-7 CAPLUS

CN L-Alaninamide,

N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-
3-[(2,6-dihydroxybenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 154674-86-9 CAPLUS

CN L-Alaninamide,

N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-
3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/284,424



RN 173305-25-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo-5-[[(phenylmethoxy) carbonyl] amino]-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173305-41-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[6-oxo-5-[[(phenylmethoxy) carbonyl] amino]-2-(2-thienyl)-1(6H)-pyrimidinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/284,424




RN 205324-41-0 CAPLUS

CN L-Alaninamide,

N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-
3-[(4-nitrobenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 222406-86-2 CAPLUS

CN L-Alaninamide,

N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-
2-oxo-3-[(pentafluorobenzoyl)oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/284,424

RN 222406-88-4 CAPLUS

CN L-.alpha.-Asparagine, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 222406-90-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-,
(3S)-4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo-

5-[[[(phenylmethyl)amino]carbonyl]amino]-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 222406-92-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-,
(3S)-4-carboxy-3-[[[2-(4-fluorophenyl)-5-[(2-furanylcarbonyl)amino]-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/284,424



RN 222406-93-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[5-[[6-(dimethylamino)-1-oxohexyl]amino]-2-(4-fluorophenyl)-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 222406-94-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo-5-[(phenylsulfonyl)amino]-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

09/284,424


Absolute stereochemistry.



RN 222406-96-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[5-amino-2-(4-fluorophenyl)-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1998:788773 CAPLUS

DOCUMENT NUMBER: 130:66805

TITLE: Preparation of peptide inhibitors of interleukin-1.β converting enzyme

INVENTOR(S): Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David J.;

09/284,424

Mullican, Michael D.; Murcko, Mark A.; Livingston, David J.
PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA
SOURCE: U.S., 106 pp., Cont.-in-part of U.S. 5,656,627.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5847135	A	19981208	US 1995-440898	19950525
US 5756466	A	19980526	US 1994-261452	19940617
US 5656627	A	19970812	US 1995-405581	19950317
US 5716929	A	19980210	US 1995-464964	19950605
WO 9535308	A1	19951228	WO 1995-US7617	19950616
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2192089	AA	19951228	CA 1995-2192089	19950616
AU 9529446	A1	19960115	AU 1995-29446	19950616
EP 784628	A1	19970723	EP 1995-925257	19950616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1159196	A	19970910	CN 1995-194381	19950616
BR 9508051	A	19971021	BR 1995-8051	19950616
HU 76622	A2	19971028	HU 1996-3475	19950616
JP 10504285	T2	19980428	JP 1995-502478	19950616
NO 9605365	A	19970217	NO 1996-5365	19961213
FI 9605036	A	19970214	FI 1996-5036	19961216
PRIORITY APPLN. INFO.:				US 1994-261452 19940617
				US 1995-405581 19950317
				US 1995-440898 19950525
				WO 1995-US7617 19950616

OTHER SOURCE(S): MARPAT 130:66805

IT 175209-21-9P 175209-22-0P 175209-42-4P
175209-46-8P 175209-83-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of peptide inhibitors of interleukin-1.beta. converting enzyme)

RN 175209-21-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[2-oxo-3-[[[(phenylmethoxy)carbonyl]amino]-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


09/284,424



RN 175209-22-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(phenylmethyl)-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-42-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[2S)-2-[(1H-imidazol-2-ylcarbonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 175209-46-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[2S)-1-oxo-2-[2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-1(2H)-pyridinyl]propyl]amino]butyl ester (9CI) (CA INDEX NAME)


09/284,424

Absolute stereochemistry.



RN 175209-83-3 CAPLUS
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[(3S)-2,3,4,5-tetrahydro-2-oxo-5-(1-oxo-3-phenylpropyl)-3-[(1-oxo-3-phenylpropyl)amino]-1H-1,5-benzodiazepin-1-yl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 36 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1998:568911 CAPLUS
DOCUMENT NUMBER: 129:184238
TITLE: Screening for thymocyte caspase activity modulators
INVENTOR(S): Reinherz, Ellis; Clayton, Linda; Ocain, Timothy D.;
Patch, Raymond J.
PATENT ASSIGNEE(S): Dana Farber Cancer Institute, USA; Procept, Inc.
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.

KIND DATE


APPLICATION NO. DATE

09/284,424


WO 9836057 A1 19980820 WO 1998-US3524 19980217
W: CA, JP
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE
PRIORITY APPLN. INFO.: US 1997-802474 19970218
 US 1997-948124 19971009
IT 191666-52-1P 211918-96-6P 211918-99-9P
 211919-00-5P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (screening for thymocyte caspase activity modulators)
RN 191666-52-1 CAPLUS
CN L-Valinamide,
N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-
4-yl]-1-oxopentyl]-L-.alpha.-aspartyl-L-.alpha.-glutamyl-N-[(1S)-1-
(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 211918-96-6 CAPLUS
CN L-Alaninamide,
N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-
4-yl]-1-oxopentyl]-L-tyrosyl-L-valyl-N-[(1S)-3-[[2,6-
bis(trifluoromethyl)benzoyl]oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI)
(CA INDEX NAME)


09/284,424

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 211918-99-9 CAPLUS
 CN L-Valinamide,
 N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-L-.alpha.-aspartyl-L-.alpha.-glutamyl-N-[(1R)-1-(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



PAGE 1-A





RN 211919-00-5 CAPLUS
 CN L-Alaninamide,
 N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-
 4-yl]-1-oxopentyl]-L-tyrosyl-L-valyl-N-[(1R)-3-[[2,6-
 bis(trifluoromethyl)benzoyl]oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



09/284,424


ACCESSION NUMBER: 1998:331708 CAPLUS
DOCUMENT NUMBER: 129:64785
TITLE: Bimodal Inhibition of Caspase-1 by Aryloxymethyl and
Acyloxymethyl Ketones
AUTHOR(S): Brady, Kenneth D.
CORPORATE SOURCE: BASF Bioresearch Corporation, Worcester, MA,
01605-4314, USA
SOURCE: Biochemistry (1998), 37(23), 8508-8515
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 151544-42-2 209055-55-0
RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)
(proteinase inhibitor; bimodal inhibition of caspase-1 by
aryloxymethyl
and acyloxymethyl ketones)
RN 151544-42-2 CAPLUS
CN L-Alaninamide,
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-
[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209055-55-0 CAPLUS
CN L-Alaninamide,
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-2-
oxo-3-(1-oxo-3-phenylpropoxy)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/284,424

applicant's PCT

L4 ANSWER 7 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1998:251152 CAPLUS

DOCUMENT NUMBER: 128:321926

TITLE: Preparation of aspartate ester inhibitors of interleukin-1.β. converting enzyme

INVENTOR(S): Albrecht, Hans P.; Allen, Hamish John; Brady, Kenneth Dale; Caprathe, Bradley William; Gilmore, John Lodge; Harter, William Glen; Hays, Sheryl Jeanne; Kostlan, Catherine Rose; Lunney, Elizabeth Ann; Para, Kimberly Suzanne; et al.

PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Albrecht, Hans P.; Allen,

Hamish John; Brady, Kenneth Dale; Caprathe, Bradley William; Gilmore, John Lodge; Harter, William Glen; Hays, Sheryl Jeanne; Kostlan, Catherine Rose

SOURCE: PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9816502	A1	19980423	WO 1997-US18514	19971009
W:	AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ,			
TM	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9749023	A1	19980511	AU 1997-49023	19971009
EP 932598	A1	19990804	EP 1997-911715	19971009
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
NO 9901677	A	19990609	NO 1999-1677	19990409
PRIORITY APPLN. INFO.:			US 1996-28322	19961011
			WO 1997-US18514	19971009

OTHER SOURCE(S): MARPAT 128:321926

IT 206863-49-2P 206863-52-7P 206863-53-8P
206863-54-9P 206863-55-0P 206863-56-1P
206863-57-2P 206863-58-3P 206863-59-4P
206863-62-9P 206863-63-0P 206863-64-1P
206863-65-2P 206863-66-3P 206863-68-5P
206863-87-8P 206863-89-0P 206863-90-3P
206863-91-4P 206863-92-5P 206863-93-6P
206863-94-7P 206863-96-9P 206863-97-0P
206864-00-8P 206864-01-9P 206864-04-2P
206864-05-3P 206864-06-4P 206864-07-5P
206864-08-6P 206864-09-7P 206864-10-0P
206864-11-1P 206864-12-2P 206864-13-3P
206864-14-4P 206864-15-5P 206864-16-6P
206864-17-7P 206864-18-8P 206864-19-9P
206864-20-2P 206864-21-3P 206864-22-4P
206864-23-5P 206864-24-6P 206864-25-7P

09/284,424

206864-26-8P 206864-27-9P 206864-28-0P

206864-29-1P 206864-30-4P 206864-31-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(prepn. of aspartate ester inhibitors of interleukin-1.beta.

converting

enzyme)


RN 206863-49-2 CAPLUS

CN 1-Naphthaleneacetic acid,

(3S)-3-[[(2S)-2-(acetyl amino)-1-oxopropyl] amino]-


4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206863-52-7 CAPLUS


CN 1-Naphthaleneacetic acid, 4-carboxy-2-oxo-3-[[1-oxo-2-[(1-oxo-4-phenylbutyl)amino]propyl]amino]butyl ester (9CI) (CA INDEX NAME)



RN 206863-53-8 CAPLUS


CN 1-Naphthaleneacetic acid, 4-carboxy-3-[[2-[(methylsulfonyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

09/284,424




RN 206863-54-9 CAPLUS
CN 1-Naphthaleneacetic acid, 3-[[[(2S)-2-[[2-(acetamino)-1-oxo-4-phenylbutyl]amino]-1-oxopropyl]amino]-4-carboxy-2-oxobutyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 206863-55-0 CAPLUS
CN 1-Naphthaleneacetic acid,
3-[[[2-(acetamino)-1-oxobutyl]amino]-4-carboxy-
2-oxobutyl ester (9CI) (CA INDEX NAME)




09/284,424

RN 206863-56-1 CAPLUS
CN 1-Naphthaleneacetic acid, 3-[[2-[(5-amino-1,5-dioxopentyl)amino]-1-oxopropyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206863-57-2 CAPLUS
CN 1-Naphthaleneacetic acid, 4-carboxy-2-oxo-3-[[1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]butyl ester (9CI) (CA INDEX NAME)




RN 206863-58-3 CAPLUS
CN 1-Naphthaleneacetic acid,
3-[[2-[(aminocarbonyl)amino]-1-oxopropyl]amino]-
4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)


09/284,424



RN 206863-59-4 CAPLUS
CN 1-Naphthaleneacetic acid,
3-[[2-(acetamido)-1-oxopropyl]amino]-4-carboxy-
2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206863-62-9 CAPLUS
CN 1-Naphthaleneacetic acid, 3-[[[2-(acetamido)acetyl]amino]-4-carboxy-2-
oxobutyl ester (9CI) (CA INDEX NAME)



RN 206863-63-0 CAPLUS
CN Benzenepropanoic acid, .beta.-phenyl-, 3-[[2-(acetamido)-1-
oxopropyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)


09/284,424



RN 206863-64-1 CAPLUS


CN L-Alaninamide, N-acetyl-L-.alpha.-glutamyl-N-[1-(carboxymethyl)-3-[(1-naphthalenylacetyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206863-65-2 CAPLUS


CN 1-Naphthaleneacetic acid, 4-carboxy-2-oxo-3-[[1-oxo-2-[(1-oxo-3-phenylpropyl)amino]propyl]amino]butyl ester (9CI) (CA INDEX NAME)




RN 206863-66-3 CAPLUS

CN 1-Naphthaleneacetic acid, 4-carboxy-3-[[2-[(3-methyl-1-oxobutyl)amino]-1-oxopropyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


09/284,424



RN 206863-68-5 CAPLUS
CN 1-Naphthaleneacetic acid, 3-[[2-[(aminocarbonyl)amino]-1-oxo-3-(phenylmethoxy)propyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206863-87-8 CAPLUS
CN 1-Naphthaleneacetic acid, 4-carboxy-3-[[[(3,4-dihydro-1-oxo-2(1H)-isoquinolinyl)acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206863-89-0 CAPLUS
CN 2-Naphthaleneacetic acid, 4-carboxy-2-oxo-3-[[[(2-oxo-6-phenyl-1-piperidiny]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

09/284,424




RN 206863-90-3 CAPLUS
CN 1-Naphthaleneacetic acid, 4-carboxy-2-oxo-3-[[2-oxo-6-phenyl-1-piperidiny]acetyl]butyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




09/284,424


RN 206863-91-4 CAPLUS
 CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-1-oxo-, 4-carboxy-3-[[3-methyl-1-oxo-2-[(1-oxo-3-phenylpropyl)amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206863-92-5 CAPLUS
 CN 2-Naphthaleneacetic acid, 4-carboxy-3-[[[(3,4-dihydro-1-oxo-2(1H)-isoquinolinyl)acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206863-93-6 CAPLUS
 CN Benzenepropanoic acid, .alpha.-(phenylmethyl)-, 4-carboxy-3-[[[(3,4-dihydro-1-oxo-2(1H)-isoquinolinyl)acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206863-94-7 CAPLUS
 CN Benzenepropanoic acid, .alpha.-(phenylmethyl)-, 4-carboxy-2-oxo-3-[[[(2-oxo-6-phenyl-1-piperidinyl)acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

09/284,424




RN 206863-96-9 CAPLUS

CN 1-Naphthaleneacetic acid, 4-carboxy-3-[[2-(3,4-dihydro-1-oxo-2(1H)-isoquinolinyl)-1-oxopropyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206863-97-0 CAPLUS

CN 2-Naphthaleneacetic acid, 4-carboxy-3-[[2-(3,4-dihydro-1-oxo-2(1H)-isoquinolinyl)-1-oxopropyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206864-00-8 CAPLUS

CN Benzenepropanoic acid, .alpha.-(phenylmethyl)-, 4-carboxy-3-[[2-(3,4-dihydro-1-oxo-2(1H)-isoquinolinyl)-1-oxopropyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)



09/284,424




RN 206864-01-9 CAPLUS

CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-1-oxo-,

4-carboxy-3-[[2-(3,4-

dihydro-1-oxo-2(1H)-isoquinolinyl)-1-oxopropyl]amino]-2-oxobutyl ester

(9CI) (CA INDEX NAME)




RN 206864-04-2 CAPLUS

1-Naphthaleneacetic acid, 4-carboxy-2-oxo-3-[[1-oxo-2-(2-oxo-3-phenyl-1-imidazolidinyl)propyl]amino]butyl ester (9CI) (CA INDEX NAME)


imidazolidinyl)propyl]amino]butyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



09/284,424

PAGE 2-A




RN 206864-05-3 CAPLUS

CN 1-Naphthaleneacetic acid,


4-carboxy-2-oxo-3-[[1-oxo-2-(tetrahydro-2-oxo-3-phenyl-1(2H)-pyrimidinyl)propyl]amino]butyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




09/284,424

PAGE 2-A




RN 206864-06-4 CAPLUS
CN 1-Naphthaleneacetic acid, 4-carboxy-2-oxo-3-[[[tetrahydro-2-oxo-3-phenyl-1(2H)-pyrimidinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




09/284,424


RN 206864-07-5 CAPLUS
CN 1-Naphthaleneacetic acid,
3-[[2-(acetamino)-3-methyl-1-oxobutyl]amino]-4-
carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206864-08-6 CAPLUS
CN Benzenepropanoic acid, .alpha.-(phenylmethyl)-, 3-[[2-(acetamino)-3-
methyl-1-oxobutyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX
NAME)




RN 206864-09-7 CAPLUS
CN Benzenebutanoic acid, .beta.-(phenylmethyl)-,
3-[[2-(acetamino)-3-methyl-
1-oxobutyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206864-10-0 CAPLUS
CN Benzenepentanoic acid, .gamma.-(phenylmethyl)-, 3-[[2-(acetamino)-3-
methyl-1-oxobutyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX
NAME)


09/284,424




RN 206864-11-1 CAPLUS
 CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-1-oxo-,
 3-[[2-(acetamino)-3-methyl-1-oxobutyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206864-12-2 CAPLUS
 CN Benzenebutanoic acid, .beta.-(phenylmethyl)-,
 4-carboxy-3-[[3-methyl-1-oxo-2-[(1-oxo-3-phenylpropyl)amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206864-13-3 CAPLUS
 CN Benzenepropanoic acid, .beta.-phenyl-, 3-[[[3-(acetamino)-2-oxo-1(2H)-pyridinyl]acetyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)




09/284,424

```


RN      206864-14-4  CAPLUS
CN      Benzenepropanoic acid, .alpha.-(phenylmethyl)-,
3-[[[3-(acetylamino)-2-oxo-
1(2H)-pyridinyl]acetyl]amino]-4-carboxy-2-oxobutyl ester (9CI)  (CA INDEX
NAME)

```



RN	206864-15-5	CAPLUS
CN	L-Valinamide, N-[(phenylmethoxy)carbonyl]-L-.alpha.-glutamyl-N-[1-(carboxymethyl)-3-[(1-naphthalenylacetyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.



RN 206864-16-6 CAPLUS
CN L-Alaninamide,
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-
[(1-naphthalenylacetyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.